Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis

[1]  D. Rockey,et al.  End-stage liver disease complications , 2013, Current opinion in gastroenterology.

[2]  A. Krag,et al.  Hyponatremia in patients treated with terlipressin: Mechanisms and implications for clinical practice , 2011, Hepatology.

[3]  M. Pavesi,et al.  Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension , 2010, Hepatology.

[4]  E. Verna,et al.  Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. , 2010, Kidney international.

[5]  A. Krag,et al.  Hyponatraemia during terlipressin therapy , 2010, Gut.

[6]  V. Arroyo,et al.  Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome , 2010, Hepatology.

[7]  D. Ackermann.  [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis]. , 2009, Therapeutische Umschau. Revue therapeutique.

[8]  P. Angus,et al.  Targeting circulatory dysfunction in cirrhosis: Terlipressin and the hepatorenal syndrome , 2009, Journal of gastroenterology and hepatology.

[9]  K. Chopra,et al.  Portal hypertension and variceal hemorrhage. , 2009, The Medical clinics of North America.

[10]  Lung-Chih Cheng,et al.  Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices , 2009, Gut.

[11]  A. Krag,et al.  Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. , 2008, American journal of physiology. Renal physiology.

[12]  A. Sanyal,et al.  Portal hypertension and variceal hemorrhage. , 2008, The Medical clinics of North America.

[13]  J. Bosch,et al.  Portal hypertension and its complications. , 2008, Gastroenterology.

[14]  J. Bosch,et al.  Clinical Manifestations and Management of Bleeding Episodes in Cirrhotics , 2008 .

[15]  D. Pateron,et al.  Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study , 2000, Hepatology.

[16]  J. Bode,et al.  Terlipressin or somatostatin for acute variceal hemorrhage. , 1997, Gastroenterology.

[17]  J. Bosch,et al.  Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. , 1996, Gastroenterology.

[18]  F. Durand,et al.  Hepatorenal syndrome , 1996, Digestive Diseases and Sciences.

[19]  C. Record,et al.  Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. , 1989, Journal of clinical gastroenterology.

[20]  M. Forsling,et al.  Conversion of triglycylvasopressin to lysine-vasopressin in man. , 1980, The Journal of endocrinology.

[21]  V. Pliska,et al.  In vivo activation of synthetic hormonogens of lysine vasopressin: Na-glycyl-glycyl-glycyl-[8-lysine]vassopressin in the cat. , 1976, Acta endocrinologica.

[22]  C. E. Siegert,et al.  Het hepatorenaal syndroom: PATHOFYSIOLOGIE EN BEHANDELING , 2010 .

[23]  Z. Mareček,et al.  Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices. , 2009, Hepato-gastroenterology.